Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIS793 + SOC in 2L mCRC
NCT04952753Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2021
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 2, randomised, open-label trial of nisevokitug in metastatic colorectal cancer (mCRC) (5 arms), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 4 weeks and Progression-Free Survival at 12 months. Started Nov 2021; status: terminated.
02
Drugs
nisevokitug
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04952753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04952753.